Pharma / Biotech

Amgen Lowers List Price for Repatha for Everyone

Effective Dec. 31, 2019, evolocumab will be distributed exclusively at the 60% lower list price of $5,850 per year and will no longer be available at its original list price.

Source link

Related posts

Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.


ED Clinical Pharmacists Speed Delivery of Lifesaving Anticoagulant Drugs


New PGx Tool Does Some Heavy Lifting


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy